CBIO insider trading
NasdaqCM HealthcareCRESCENT BIOPHARMA, INC.: insider trade history from SEC Form 4 filings.
About CRESCENT BIOPHARMA, INC.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
Company website: crescentbiopharma.com
CBIO insider activity at a glance
FilingIQ tracks 183 insider transactions for CBIO in filings since Aug 20, 2015. The most recent transaction is dated Sep 18, 2026.
Across the full history, 25 open-market purchases
and 33 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on CBIO insider trades is 59.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest CBIO Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for CBIO?
- FilingIQ tracks 183 Form 4 insider transactions for CBIO (CRESCENT BIOPHARMA, INC.), covering filings from Aug 20, 2015 onwards. 10 of those are dated within the last 90 days.
- Are CBIO insiders net buyers or net sellers?
- Across the full Form 4 history for CBIO, 25 transactions (14%) were open-market purchases and 33 (18%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does CBIO insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is CBIO in?
- CRESCENT BIOPHARMA, INC. (CBIO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $411.03M.
Methodology & sources
Every CBIO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.